Cingulate Inc
CING5.372USD
+0.272+5.33%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
20.55MCap. mercado
PérdidaP/E TTM
Más Datos de Cingulate Inc Compañía
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Información de la empresa
Símbolo de cotizaciónCING
Nombre de la empresaCingulate Inc
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoDr. Shane J. Schaffer, Pharm.D.
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 07
Dirección1901 W. 47Th Place
CiudadKANSAS CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal66205
Teléfono19139422300
Sitio Webhttps://www.cingulate.com/
Símbolo de cotizaciónCING
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoDr. Shane J. Schaffer, Pharm.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Werth Family Investment Associates LLC
1.90%
Commonwealth Financial Network
1.08%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.43%
The Vanguard Group, Inc.
0.21%
Other
95.79%
Accionistas
Accionistas
Proporción
Werth Family Investment Associates LLC
1.90%
Commonwealth Financial Network
1.08%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.43%
The Vanguard Group, Inc.
0.21%
Other
95.79%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
2.37%
Corporation
2.32%
Investment Advisor/Hedge Fund
0.70%
Research Firm
0.05%
Individual Investor
0.01%
Other
94.55%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
44
238.41K
5.46%
-49.05K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
2023Q1
34
15.09K
32.03%
-921.00
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Werth Family Investment Associates LLC
97.99K
2.31%
--
--
Apr 14, 2025
Commonwealth Financial Network
55.52K
1.31%
+12.50K
+29.05%
Mar 31, 2025
Geode Capital Management, L.L.C.
30.40K
0.72%
+3.08K
+11.26%
Mar 31, 2025
UBS Financial Services, Inc.
22.12K
0.52%
+9.92K
+81.34%
Mar 31, 2025
The Vanguard Group, Inc.
10.76K
0.25%
+8.76K
+438.54%
Mar 31, 2025
Quantum Private Wealth, LLC
10.00K
0.24%
+10.00K
--
Mar 31, 2025
Alphamark Advisors, LLC
5.01K
0.12%
+5.00K
+50000.00%
Dec 31, 2024
Fountainhead Shrugged, LLC
3.37K
0.08%
--
--
Apr 14, 2025
BofA Global Research (US)
1.96K
0.05%
+2.00
+0.10%
Mar 31, 2025
Tower Research Capital LLC
433.00
0.01%
-331.00
-43.32%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Fecha
Tipo
Relación
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Aug 07, 2024
Merger
12<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
Nov 28, 2023
Merger
20<1
